Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 8/10/21 → 7/11/23 |
Allogeneic CRISPR-Cas9 Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies
- Hildebrandt, Gerhard (PI)
| Status | Active |
|---|---|
| Effective start/end date | 8/10/21 → 7/11/23 |